OncoMatch/Clinical Trials/NCT06678659
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Is NCT06678659 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies REC-1245 for unresectable.
Treatment: REC-1245 — This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic anti-cancer treatment — for a given tumor type
Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
Cannot have received: RBM39 degrader
Received treatment with another RBM39 degrader
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Cleveland Clinic · Cleveland, Ohio
- SCRI Oncology Partners - PPDS · Nashville, Tennessee
- START Mountain Region · West Valley City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06678659 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior RBM39 degrader disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify